Related Experiment Video
Updated: Oct 17, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Stephanie M Kaiser1, Sruthi Arepalli1, Justis P Ehlers1
1Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract:
Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
FDA Approved Drugs: Changes to Approved Drugs
Regulation of Angiogenesis and Blood Supply
Glaucoma: Overview
iPS Cell Differentiation

